Advanced
Trials portfolio
ANIMATE
A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first or second line salvage therapy
Single-arm, open label, multicentre phase IItrial.
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
AVENuE
Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study
AVENuE is a non-randomised, single arm Phase II trial investigating how patients with newly diagnosed, untreated advanced classical Hodgkin lymphoma respond to treatment with the monocolonal antibody, [...]
Area: Haematological cancer
Phase: Phase II
Status: In set-up (funded)
BCT
PHASE II STUDY OF BORTEZOMIB CONSOLIDATION AFTER HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA
BCT is a non-randomised, single arm, multicentre, phase II trial of bortezomib consolidation after high dose therapy (HDT) and autologous stem cell transplantation (ASCT) for patients with multiple my [...]
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
Cardamon
Carfilzomib/Cyclophosphamide/Dexamethasone with maintenance carfilzomib in untreated transplant-eligible patients with symptomatic MM to evaluate the benefit of upfront ASCT
Cardamon is a randomised (1:1), multicentre, phase II trial of carfilzomib, cyclophosphamide and dexamethasone (CarCyDex) as induction in untreated patients with symptomatic multiple myeloma who are c [...]
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
CORAL
Randomised study of ICE + Rituximab (R-ICE) versus DHAP Rituximab (R-DHAP) in previously treated patients with CD20 positive diffuse large B-cell Non-Hodgkins lymphoma, eligible for high dose chemotherapy followed by randomised maintenance treatment with Rituximab
CORAL is a multicentre, phase III open-label, randomized trial evaluating the efficacy of R-ICE compared to R-DHAP with previously treated diffuse large B-cell lymphoma, followed by high-dose chemothe [...]
Area: Haematological cancer
Phase: Phase III
Status: Closed
HOVON 127 Burkitt Lymphoma
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
HOVON 127 BL is a randomized, open-label, prospective, multicentre phase III study. All eligible patients will be randomized to receive either R-CODOX-M/R-IVAC or DA-EPOCH-R.
Area: Haematological cancer
Phase: Phase III
Status: In set-up (funded)
IDRIS
Phase III randomised trial of immunomodulatory therapy in high risk solitary bone plasmacytoma
IDRIS is a multicentre randomised phase III study investigating whether a combination of lenalidomide and dexamethasone can delay or prevent disease progression in patients with newly-diagnosed solita [...]
Area: Haematological cancer
Phase: Phase III
Status: Active (recruiting)
INCA
A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin (INO) plus Rituximab and CVP (IO-R-CVP) versus Gemcitabine plus Rituximab and CVP (Gem-R-CVP) for the first line treatment of patients with Diffuse Large B Cell Lymphoma (DLBCL) who
INCA is a multicentre, randomised, phase II trial comparing IO-R-CVP with Gem-R-CVP in the first line treatment of patients with DLBCL who are not fit for anthracycline-containing chemotherapy.
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
MCL MiniAllo
Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma
MCL MiniAllo is a single arm, non−randomised phase II study investigating the use of reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma in first remission.
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
PADIMAC
Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT.
PADIMAC is non-randomised, single arm, multicentre phase II trial evaluating the safety of multiple myeloma patients that have achieved a Complete Response (CR) or Very Good Partial Response (VGPR) po [...]
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
PAIReD
Phase II study of reduced intensity allogeneic transplantation for refractory Hodgkin lymphoma
PAIReD is a multicentre phase II single-arm trial of BEAM-Campath conditioned reduced intensity stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma.
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
PembroWM
A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström’s macroglobulinaemia
A phase II, non-randomised, single arm, open-label trial.
Area: Haematological cancer
Phase: Phase II
Status: In set-up (funded)
PORT
Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T cell lymphoma
PORT is a multicentre, single arm, phase II trial of pembrolizumab in combination with radiotherapy for patients with relapsed/refractory CTCL.
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
PRIMA
A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of response with chemotherapy plus Rituximab in comparison with no maintenance therapy
PRIMA is an open label, international, multicentre, randomiszed study with two treatment phases. During the first phase, patients will be evaluated for response to different induction regimens. In the [...]
Area: Haematological cancer
Phase: Phase III
Status: Closed
ProT4
Multicentre randomised phase II study to evaluate the efficacy of prophylactic transfer of CD4 lymphocytes after T-cell depleted reduced intensity HLA-identical sibling transplantation for haematological cancers
ProT4 is a multicentre, randomised phase II trial to evaluate the efficacy of prophylactic transfer of donor CD4 lymphocytes after T-cell depleted reduced intensity allogeneic transplantation for haem [...]
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
R2W
Randomised phase 2 trial in WM - Subcutaneous Bortezomib, Clycophosphamide and Rituximab (BCR versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for initial therapy of Waldenstr?m’s macroglobulinaemia (WM): a randomised phase II trial
R2W is a randomised (2:1), non-comparative, multicentre, phase II trial of bortezomib, cyclophosphamide and rituximab (BCR – experimental) versus fludarabine, cyclophosphamide and rituximab (FCR – con [...]
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
RAPID
A Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin’s Disease
A randomised (1:1), multicentre, phase III trial to determine whether patients with clinical stage IA/IIA Hodgkin’s disease who have a negative FDG-PET scan after 3 cycles of ABVD require consolidatio [...]
Area: Haematological cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
RATHL
A randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma
RATHL is a multi-centre randomised trial comparing treatment outcome for patients with advanced Hodgkin lymphoma, using FDG-PET imaging after 2 cycles of ABVD to determine response and subsequent mana [...]
Area: Haematological cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
R-CHOP 14 vs 21
A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin’s lymphoma.
A multicentre randomised trial comparing R-CHOP 14 given for 6 cycles with R-CHOP 21 given for 8 cycles in patients with newly diagnosed CD20 positive diffuse large B cell lymphoma, bulky stage IA to [...]
Area: Haematological cancer
Phase: Phase III
Status: Closed
ReBeL
ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients >= 18 years with relapsed follicular lymphoma. A HOVON/GLSG/NCRI study
ReBeL is a prospective, randomised, multicentre, international phase II trial (phase I is not being conducted in the UK). ReBeL has two experimental arms; lenalidomide and rituximab versus lenalidomid [...]
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
RETRO-CHOP
A retrospective translational study: Characterisation of molecular predictors of outcome in patients with diffuse large B cell lymphoma treated on the R-CHOP14 vs 21 multicentre trial
This is a retrospective study which aims to perform biomarker analyses on archived samples from patients with diffuse large B cell lymphoma (DLBCL) who have been treated on the R-CHOP 14 vs 21 multice [...]
Area: Haematological cancer
Phase: Tissue collection
Status: Active (recruiting)
RIC UCBT
Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning Regimen
RIC-UCBT is a multicentre phase II single-arm trial of reduced-intensity conditioned umbilical cord blood transplantation in patients with haematological diseases.
Area: Haematological cancer
Phase: Phase II
Status: Closed
Triangle
Autologous transplantation after a rituximab/ ibrutinib/ Ara-C containing induction in generalized mantle cell lymphoma – a randomized European MCL network trial.
Triangle is a randomized, three-arm, parallel-group, open label international phase III trial.
Area: Haematological cancer
Phase: Phase III
Status: In set-up (funded)
UKALL14
A randomised trial for adults with newly diagnosed acute lymphoblastic leukaemia
UKALL14 is a Phase III multicentre randomised trial for adults with newly-diagnosed Acute Lymphoblastic Leukaemia (ALL). The main randomisations investigate standard induction chemotherapy with or wit [...]
Area: Haematological cancer
Phase: Phase III
Status: Active (recruiting)
UKALL60
A Phase 2 study for older adults with Acute Lymphoblastic Leukaemia
UKALL60+ is a multicentre, non-randomised Phase II trial forolder patients with Acute Lymphoblastic Leukaemia (ALL). There are four treatment pathways based on standard practice here in the UK and in [...]
Area: Haematological cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
UK-Haplo
UK-Haplo: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
UK Haplo is a multicentre, non-randomised Phase II trial in patients with haematological malignancies to investigate whether it is possible to carry out haploidentical peripheral blood stem cell trans [...]
Area: Haematological cancer
Phase: Phase II
Status: Active (recruiting)
Watch & Wait
An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a)
The Watch and Wait study is a randomised phase III trial to determine whether giving treatment with rituximab to patients with advanced stage asymptomatic follicular lymphoma (grades 1, 2 and 3a) resu [...]
Area: Haematological cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2019 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us